Literature DB >> 15859545

[Thymectomy in myasthenia gravis].

Witold Rzyman1, Jan Skokowski, Tomasz Marjański, Agnieszka Walczak, Amelia Szymanowska, Małgorzata Bilinska.   

Abstract

OBJECTIVES AND METHODS: To evaluate the results of thymectomy in myasthenia gravis we performed retrospective analysis of 82 consecutive patients in the mean age of 39 +/- 15 treated between 1991 and 2001. All patients underwent extended thymectomy by median sternotomy. Follow-up was assessed in 74 of 81(91.4%) patients, in the mean age of 39 +/- 15, discharged from the Department.
RESULTS: Fifty three (71.6%) patients had symptoms of myasthenia gravis for less than 2 years. According to Osserman's classification 8 (10.8%) patients were assessed as class I, 32 (43.2%) as IIA 26 (35.2%) as IIB and 8 (10.8%) as IIC. In the postoperative period 8 (10.8%) patients had respiratory insufficiency, 5 (6.8%) were reoperated for bleeding. One patient died (1.4%) due to bilateral pneumonia and pulmonary insufficiency. After thymectomy the improvement of patient's clinical status was observed in 46 patients (86.4%) and complete remission was in 13 patients (17.6%). Prompt improvement after thymectomy (p = 0.008) and short duration of symptoms (p = 0.036) are positive predictive factors. Patients in class I had significantly better prognosis concerning complete remission (p = 0.036). Age, gender, histology of the thymus, and type of the thymoma had no influence on long time follow up.
CONCLUSIONS: Extended thymectomy is a safe procedure leading to the improvement in majority of patients treated for myasthenia gravis.

Entities:  

Mesh:

Year:  2005        PMID: 15859545

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  1 in total

1.  Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma.

Authors:  Jian-Ping Xu; Xue-Zhi Hao; Xiang-Ru Zhang; Sheng Yang; Yuan-Kai Shi
Journal:  Thorac Cancer       Date:  2015-11-27       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.